Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Allergy Medicine
Protein fused to Fc epsilon receptor enhances lymphocyte responses
September 8th, 2004
CTLA-4 recombinant protein genetically fused to canine Fc epsilon receptor I alpha enhances allergen-specific lymphocyte responses in experimentally sensitized dogs. "Vaccination with a recombinant antigen fused to a targeting molecule is a potential strategy for inducing efficient immune responses. For the therapeutic purpose of allergic diseases in dogs, a DNA construct which expresses recombinant fusion protein with two functional domains, cytotoxic T lymphocyte antigen (CTLA-4) and Fc-epsilon receptor I-alpha, was developed to bridge antigen-presenting cells and I-E-allergen complex. The recombinant fusion protein expressed by the DNA construct was demonstrated to...
Source: Vaccine Weekly (2004-09-08)
|
